NEUROMYELITIS OPTICA SPECTRUM DISORDER
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New study tracks Long-Term immune effects of NMOSD drug
Disease control OngoingThis study looks at the long-term safety of the drug inebilizumab in people with NMOSD, a rare autoimmune disease that affects the nerves. Researchers will measure immune cells and antibody levels in 32 adults who have already been on the drug for at least two years. The goal is …
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 09:25 UTC
-
New drug shows promise in preventing devastating NMOSD attacks
Disease control OngoingThis study tests a drug called MIL62 in 102 adults with NMOSD, a rare autoimmune disease that attacks the optic nerves and spinal cord. The goal is to see if MIL62 can safely prevent relapses (sudden worsening of symptoms). Participants receive MIL62 and are monitored for side ef…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 09:24 UTC
-
New device aims to improve walking in rare nerve disease
Symptom relief ENROLLING_BY_INVITATIONThis study tests a device called MR-C-014 to see if it is safe and acceptable for people with neuromyelitis optica spectrum disorder (NMOSD) who have trouble walking. About 30 adults aged 18-70 will use the device for 8 weeks, walking 3 times per week. Researchers will measure ho…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: NA • Sponsor: MedRhythms, Inc. • Aim: Symptom relief
Last updated May 26, 2026 09:23 UTC
-
800 NMOSD patients join landmark registry to unlock disease secrets
Knowledge-focused ENROLLING_BY_INVITATIONThis study is a registry that will follow about 800 adults with neuromyelitis optica spectrum disorder (NMOSD) across North America. Researchers will collect information on how the disease presents, progresses, and is managed over time. The goal is to better understand NMOSD and …
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC
-
Scientists launch Long-Term study to uncover secrets of rare brain and spinal cord diseases
Knowledge-focused OngoingThis study follows 150 people with rare nerve and immune system disorders like Neuromyelitis Optica and Transverse Myelitis. Researchers collect health data and blood samples over time to learn what causes inflammation, why some treatments work better for some people, and what ha…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC